Shares of Hypera S.A. (OTCMKTS:HYPMY – Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as $4.61 and last traded at $4.90, with a volume of 5224 shares traded. The stock had previously closed at $4.93.
Hypera Stock Performance
The business has a 50 day moving average price of $5.21 and a 200-day moving average price of $5.55. The company has a market capitalization of $3.10 billion, a price-to-earnings ratio of 9.18 and a beta of 1.04.
Hypera (OTCMKTS:HYPMY – Get Free Report) last issued its earnings results on Thursday, July 25th. The company reported $0.15 earnings per share (EPS) for the quarter. The company had revenue of $420.00 million for the quarter.
About Hypera
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
See Also
- Five stocks we like better than Hypera
- What is a Secondary Public Offering? What Investors Need to Know
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Canada Bond Market Holiday: How to Invest and Trade
- 2 Energy Stocks Fueling the AI Datacenter Boom
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.
